These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 11843764)

  • 1. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis.
    Rønager J; Ravnborg M; Hermansen I; Vorstrup S
    Artif Organs; 2001 Dec; 25(12):967-73. PubMed ID: 11843764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka KV
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD002277. PubMed ID: 23235588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IVIG and PLEX in the treatment of myasthenia gravis.
    Bril V; Barnett-Tapia C; Barth D; Katzberg HD
    Ann N Y Acad Sci; 2012 Dec; 1275():1-6. PubMed ID: 23278570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of IVIg and PLEX in patients with myasthenia gravis.
    Barth D; Nabavi Nouri M; Ng E; Nwe P; Bril V
    Neurology; 2011 Jun; 76(23):2017-23. PubMed ID: 21562253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2003; (2):CD002277. PubMed ID: 12804431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment.
    Abraham A; Lovblom LE; Bril V
    Can J Neurol Sci; 2019 Nov; 46(6):762-766. PubMed ID: 31322098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
    Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin.
    Gajdos P; Chevret S
    Ann N Y Acad Sci; 2008; 1132():271-5. PubMed ID: 18096850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients.
    Alipour-Faz A; Shojaei M; Peyvandi H; Ramzi D; Oroei M; Ghadiri F; Peyvandi M
    Acta Neurol Belg; 2017 Mar; 117(1):245-249. PubMed ID: 27530310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up.
    Triantafyllou NI; Grapsa EI; Kararizou E; Psimenou E; Lagguranis A; Dimopoulos A
    Ther Apher Dial; 2009 Jun; 13(3):174-8. PubMed ID: 19527462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis.
    Barnett C; Wilson G; Barth D; Katzberg HD; Bril V
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):94-7. PubMed ID: 23154126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2006 Apr; (2):CD002277. PubMed ID: 16625559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of response to immunomodulation in patients with myasthenia gravis.
    Katzberg HD; Barnett C; Bril V
    Muscle Nerve; 2012 May; 45(5):648-52. PubMed ID: 22499090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.
    Heatwole C; Johnson N; Holloway R; Noyes K
    J Clin Neuromuscul Dis; 2011 Dec; 13(2):85-94. PubMed ID: 22361692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
    Illa I
    J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis.
    Furlan JC; Barth D; Barnett C; Bril V
    Muscle Nerve; 2016 Jun; 53(6):872-6. PubMed ID: 26521889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis.
    Jensen P; Bril V
    J Clin Neuromuscul Dis; 2008 Mar; 9(3):352-5. PubMed ID: 18344718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic plasma exchange in a patient of myasthenic crisis, refractory to intravenous immunoglobulin and immunosuppressive therapy.
    Prakash S; Hans R; Sharma RR; Lal V; Marwaha N
    Neurol India; 2017; 65(6):1409-1412. PubMed ID: 29133726
    [No Abstract]   [Full Text] [Related]  

  • 20. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial.
    Katzberg HD; Barnett C; Merkies IS; Bril V
    Muscle Nerve; 2014 May; 49(5):661-5. PubMed ID: 24810970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.